% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

macugen_rules 136 posts  |  Last Activity: 10 hours ago Member since: Jul 18, 2005
  • Reply to

    ACHN back to higher levels.

    by doriangilbert Oct 5, 2015 8:59 AM
    macugen_rules macugen_rules 10 hours ago Flag

    There are Fools and there are Fools. At least in your case, you openly admit your Pain unlike the others Flappers. Old Hag Magpie is starring at his Huge Losses in his 2k January 2016 15 calls. And Yup the lying Old Milfie always says she sold before any collapse with Huge Gains!LMFAO.

  • Reply to

    Another one bites the dust

    by macugen_rules 11 hours ago
    macugen_rules macugen_rules 10 hours ago Flag

    You longs keep ignoring the facts AL-335 is still an unknown and unproven compound. You keep saying JNJ invested 225 millions then they must know. No doubt they know 3102 is Safe. I am not denying that. What if ethe combo Al-335+Simeprevir produces Toxicity. For your Sake; you hope and pary that wasn't the case or else this stock will trade in the 3s. So keep those Flapping noises down!LMFAO.

  • Which ones of you are in ADXS. I counted at least two Flappers.

  • macugen_rules by macugen_rules Oct 2, 2015 9:14 AM Flag

    the HepC Field. Others are late to the party

    ' We find the 89% SVR4 encouraging in treatment-naïve cirrhotic GT3 patients from a 6-week treatment duration with Gilead’s’s triple combo (Sofosbuvir + GS-5816 + GS-9857). This is a high-end SVR relative to the historical rates in a very difficult patient population. Although the data are based off relatively small numbers of patients, the fact that the combo printed 100% SVR4 in GT3 treatment-experienced cirrhotics (even harder to treat) with 8 weeks’ duration suggests this combo is going to do very well in ph3 registrational studies in all GT’s, with short duration. In our view, this initial data suggests that Wave-4 works, and we continue to think it could hit the market by 2017 and support Gilead’s continued dominance in HCV (though we model lots of competition). At the conference, we look to the full SVR12 data for all groups, as well as data from Merck’s (MRK) triple (which appears to be a late-breaker).'
    Janssen/Achillion who???

  • Reply to

    I Don't Know About the Rest of the Longs

    by kwantung07 Sep 30, 2015 12:31 PM
    macugen_rules macugen_rules Oct 1, 2015 7:37 PM Flag

    There is No News nor any catalyst in any foreseen Future. This Shameless Pumper is now the spoke person for Old Hag Magpie aka magnam_pi who have been misleading this board since last September.
    these dudes and dudettes have No Integrity what so ever.

  • Reply to

    I Don't Know About the Rest of the Longs

    by kwantung07 Sep 30, 2015 12:31 PM
    macugen_rules macugen_rules Oct 1, 2015 7:26 PM Flag

    You Shameless Pumper.What Plethora of News?. Name one. You buy it's your money but DO NOT mislead others like Old Hag Magpie. Have you No Shame Wanton Cart Pusher!LMAO.

  • macugen_rules macugen_rules Oct 1, 2015 1:06 PM Flag

    This stock shouldn't be trading at this level considering the outstanding number of shares divided by cash on hand. Any Milestones stone payment would not come until the year 2020 to 2022 if all Trials by Janssen gone well. The stock should be traded at cash value at best.
    Time will tell if I am right on this projection.

  • Reply to

    One thing is for certain

    by ugotsuckeredin Sep 30, 2015 11:41 AM
    macugen_rules macugen_rules Sep 30, 2015 12:20 PM Flag

    They won't need another Dilution for any foreseen Future as the Money from JNJ will heir guaranteed their lavish Lifestyle for years to come. The Extra 8000 square feet of so called office Space!!! Why??. More perks for Achillion LaLa Land where a Heated Pool festonned with Gazebos and Fake Palm Trees are the ticket for Employees' Morale. Hey after a long day at work (what Work???); Desh needs to relax. A 1985 Dom Perignon, well iced a routine afternoon Drink. Maybe a few more Dolls for Desh;s Aerobics Lap dance to round out his hard day at his Opulent Office!....A Job well Done as usual!LMFAO.

  • Reply to

    The Tard Mac

    by arnoldd70 Sep 29, 2015 1:31 PM
    macugen_rules macugen_rules Sep 29, 2015 2:33 PM Flag

    Say it again mr.KnowNothing. Which Phase 1 (In Human) is completed. Where is the Data for such Phase1 Football head??. At last November 2014 AASLD presentation, Alios only gave out Cell based Replicon Assay. In other word, an In Vitro testing you Fool.!LMFAO.

  • Reply to

    Sidelurker is preparing

    by macugen_rules Sep 24, 2015 9:35 AM
    macugen_rules macugen_rules Sep 24, 2015 3:13 PM Flag

    The Royal Screw-up with No upfront cash. Your CEO and its board of directors already cashed in and deposit money from the 18.4 million shares sold to JJDV. Contract are bound as there wasn't any Clause for the filing indicating break up fees if such a thing happens. As I keep saying the only thing worth fro you longs here is none than 3102 and its valued at 225 millions!LMAO.
    2020 is when JNJ would have a viable 2 or 3 DAAs regimen to compete. You guys have more to worry than the shorts. Any Toxicity creeps up then Janssen would abandon this joint venture. As for now, you have been handed the short end of the stick. Like I say everything at Achillion's land is a Party day. Paychecks keep coming every two weeks......Desh is mumbling all along 'I get you good Suckas'!LOL.

  • Reply to

    Sidelurker is preparing

    by macugen_rules Sep 24, 2015 9:35 AM
    macugen_rules macugen_rules Sep 24, 2015 2:01 PM Flag

    Ask yourself this?. What Binary Event Achillion has in the future. No prelude to any Halt. Your snake oil salesman of a CEO regurgitated the same old song and he dance for the proxy studies of 3102 with Sofos during the last presentation. This time the Street ain't buying it resulting in a buck and change for the low 7s. The Tap Dance would wane with time. Why would it take so long for Janssen/Alios to release POC of AL-335?

  • Reply to


    by rodsauve Sep 24, 2015 11:18 AM
    macugen_rules macugen_rules Sep 24, 2015 1:45 PM Flag

    Wrong Again!. Gilead's first human data on its drug targeting TLR7 (Toll like Receptor 7) for HBV is expected by year-end. Not counting NDA and EMA enablings by end of 2015 for HVC. Another game changer.
    Strong and Hold.

    Sentiment: Strong Buy

  • Reply to

    Sidelurker is preparing

    by macugen_rules Sep 24, 2015 9:35 AM
    macugen_rules macugen_rules Sep 24, 2015 10:54 AM Flag

    There are smart shorts and there are stupid shorts. My Algos tell me to the minute when to Hold or Fold. When I short a particular stock, I have done more Homework that you!LMAO.
    It's people like lurker boy who get creamed days in days out. Or people like you who didn't see warning signs about ACHN rolling over since January of this year.

  • macugen_rules by macugen_rules Sep 24, 2015 9:35 AM Flag

    To move out of his single wide. Yup poor sap is creamed shorting ARWR and CNAT!LMFAO.

  • Reply to

    Sdelurker's Confession

    by macugen_rules Sep 23, 2015 5:23 PM
    macugen_rules macugen_rules Sep 23, 2015 7:14 PM Flag

    A Berserker to boot!LMFAO.

  • macugen_rules by macugen_rules Sep 23, 2015 5:23 PM Flag

    This post will be sticky. Told ya not to Flap!LMAO.

    macugen_rules • Aug 15, 2014 9:48 AM Remove 5users liked this postsusers disliked this posts0Reply
    I warned you on many occasions. I gave you the Data from March 14 from the -007 trial in Australia where all patients achieved 100% cure rate (SVR12) even for the one with all baseline mutations. The same Data were submitted to the FDA for the Hold removal of 1625. You chose to ignore the Facts. I hope you only shorted the stock verbally just to irritate the Folks here otherwise you are ruined! Less

    Confession of a dead broke Lurker Boy!LOL.

    sidelurker • Aug 15, 2014 2:06 PM Flag
    6users liked this postsusers disliked this posts0Reply
    I know, I know......I had been quiet for the last 2 - 3 days for a reason, you know where I'm going with this. I went berzerk on yahoo msg board after I temporary lost my mind; seeing how this latest run-up didn't have a traditional pullback. Signals were there flashing for me to cover.....stupid of me. Today's news just rocked me over, I'm done....hit a margin call.

    BTW - Good luck to you, Mac. You are indeed a good man for trying to warn me. Hope ACHN gets bought out and you make a killing. I may be back one day after this major setback and go long instead ;-)


    SL Less

  • Reply to

    ACHN deviating from IBB - 3 times in past 4 days

    by sidelurker Sep 23, 2015 3:24 PM
    macugen_rules macugen_rules Sep 23, 2015 4:06 PM Flag

    Does it really matter?. How much did your broker clean your clock last August when you shorted the stock in the 4s and 5s. and until recently?. Do you want me to bring back Sidelurker's Confession?!LMAO.

  • Reply to

    ACHN deviating from IBB - AGAIN!

    by sidelurker Sep 21, 2015 2:01 PM
    macugen_rules macugen_rules Sep 21, 2015 4:11 PM Flag

    And How Much did you Lose shorting ACHN in the 4 and 5s back then and until recently. Remember I still have your posts well archived....Now that's a LMFAO!

    Sentiment: Sell

  • macugen_rules by macugen_rules Sep 21, 2015 1:52 PM Flag

    Strong Buy and Hold.
    SVR12 Pan Genotypic 1 through 6, 1035 patients . Late stage studies ASTRAL 1 through ASTRAL 4.

    Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes

    If Approved, SOF/VEL Would be the First All-Oral Pan-Genotypic Single Tablet Regimen for Chronic HCV-

    - U.S. NDA and European MAA Submissions Planned for Q4 2015 -

    Sentiment: Strong Buy

  • Reply to

    The 1800 lbs Gorilla

    by macugen_rules Sep 21, 2015 1:38 PM
    macugen_rules macugen_rules Sep 21, 2015 1:47 PM Flag

    Freaking Yahoo just won't allow the entire content to go through. All you straws grasping need to know are:
    SVR12, 1035 patients genotype 1-6--------ASTRAL1 through 4. This stock will fizzle as usual after they pumped high enough so dumpage will follow!LOL.

    - U.S. NDA and European MAA Submissions Planned for Q4 2015 -

    Sentiment: Sell

109.46-5.06(-4.42%)Oct 6 4:00 PMEDT